These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 30091312

  • 1. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB, Rho CR, Shin JA, Lyu J, Kang S.
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J, Randoll N, Lucius R, Caliebe A, Roider J, Klettner A.
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ, Chao YM, Liu NC, Chan JY.
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [Abstract] [Full Text] [Related]

  • 4. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L, Fuhrer R, Zinkernagel M, Enzmann V.
    Ophthalmologica; 2019 Dec; 241(3):137-142. PubMed ID: 30001546
    [Abstract] [Full Text] [Related]

  • 5. Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.
    Vo TA, Abedi S, Schneider K, Chwa M, Kenney MC.
    Exp Eye Res; 2018 Dec; 177():112-116. PubMed ID: 30071215
    [Abstract] [Full Text] [Related]

  • 6. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N, Terasaki H, Shirasawa M, Kawano H, Sonoda S, Yamaguchi M, Hashiguchi T, Hisatomi T, Ishibashi T, Sakamoto T.
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [Abstract] [Full Text] [Related]

  • 7. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
    Puddu A, Sanguineti R, Traverso CE, Viviani GL, Nicolò M.
    Eur J Ophthalmol; 2016 Aug 04; 26(5):425-30. PubMed ID: 27079208
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept.
    Ranjbar M, Brinkmann MP, Zapf D, Miura Y, Rudolf M, Grisanti S.
    Cell Physiol Biochem; 2016 Aug 04; 38(2):737-47. PubMed ID: 26871551
    [Abstract] [Full Text] [Related]

  • 10. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
    Dinç E, Ayaz L, Kurt AH.
    J Ocul Pharmacol Ther; 2018 May 04; 34(4):346-353. PubMed ID: 29389239
    [Abstract] [Full Text] [Related]

  • 11. Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells.
    Kang S, Choi H, Rho CR.
    J Ocul Pharmacol Ther; 2016 Dec 04; 32(10):671-676. PubMed ID: 27827554
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A, Recber M, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct 04; 252(10):1593-8. PubMed ID: 25047874
    [Abstract] [Full Text] [Related]

  • 13. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia.
    Bahrami B, Shen W, Zhu L, Zhang T, Chang A, Gillies MC.
    Clin Exp Ophthalmol; 2019 Nov 04; 47(8):1074-1081. PubMed ID: 31265210
    [Abstract] [Full Text] [Related]

  • 14. Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy.
    De Cillà S, Farruggio S, Vujosevic S, Raina G, Filippini D, Gatti V, Clemente N, Mary D, Vezzola D, Casini G, Rossetti L, Grossini E.
    Cell Physiol Biochem; 2017 Nov 04; 42(5):1725-1738. PubMed ID: 28743128
    [Abstract] [Full Text] [Related]

  • 15. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M, Fernández-Robredo P, Hernández M, Bezunartea J, Reiter N, Recalde S, García-Layana A.
    Biochem Pharmacol; 2016 Mar 01; 103():129-39. PubMed ID: 26793998
    [Abstract] [Full Text] [Related]

  • 16. Aflibercept and Ranibizumab Modulate Retinal Pigment Epithelial Cells Function by Acting on Their Cross Talk with Vascular Endothelial Cells.
    De Cillà S, Farruggio S, Cocomazzi G, Mary D, Alkabes M, Rossetti L, Vujosevic S, Grossini E.
    Cell Physiol Biochem; 2020 Feb 12; 54(2):161-179. PubMed ID: 32045141
    [Abstract] [Full Text] [Related]

  • 17. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
    Borchers L, Roider J, Klettner A.
    Ophthalmic Res; 2021 Feb 12; 64(3):369-388. PubMed ID: 33011724
    [Abstract] [Full Text] [Related]

  • 18. Effect of Long-term Anti-VEGF Treatment on Viability and Function of RPE Cells.
    Brinkmann A, Winkelmann K, Käckenmeister T, Roider J, Klettner A.
    Curr Eye Res; 2022 Jan 12; 47(1):127-134. PubMed ID: 33998943
    [Abstract] [Full Text] [Related]

  • 19. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
    Schnichels S, Hagemann U, Januschowski K, Hofmann J, Bartz-Schmidt KU, Szurman P, Spitzer MS, Aisenbrey S.
    Br J Ophthalmol; 2013 Jul 12; 97(7):917-23. PubMed ID: 23686000
    [Abstract] [Full Text] [Related]

  • 20. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
    Terasaki H, Sakamoto T, Shirasawa M, Yoshihara N, Otsuka H, Sonoda S, Hisatomi T, Ishibashi T.
    Retina; 2015 May 12; 35(5):1007-15. PubMed ID: 25627091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.